View Older Stories
-
Scilex approves cryptocurrency token dividend for shareholders
-
Scilex Holding (SCLX) files $500M mixed shelf
-
Datavault AI expects revenue jump to $30 million in fiscal 2025
-
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026
-
Scilex announces Dream Bowl 2026 meme coin distribution begins Dec. 24
-
Scilex increases loan facility to $100 million with pledge of more shares
-
Scilex completes $583.3 million investment in Datavault AI
-
Datavault AI completes second tranche with Scilex for 1,237.6 Bitcoin
-
Scilex raises $20.3 million through warrant exercise
-
Scilex raises $20.3 million through warrant exercise agreement
-
Datavault AI reports 148% revenue growth, raises 2026 guidance to $200M
-
Datavault AI approves meme coin distribution to shareholders
-
Datavault AI reports 467% revenue growth, secures $150M investment
-
Datavault AI sets Nov 14 record date for Dream Bowl meme coin distribution
-
Datavault AI converts $13.3 million in convertible debt
-
Scilex completes first tranche of Oramed warrant repurchase for $13 million
-
Datavault AI closes initial tranche of $150 million Bitcoin investment deal
-
Scilex closes initial $150 million Bitcoin investment in Datavault AI
-
Scilex to invest $150 million in bitcoin in Datavault AI deal
-
Scilex completes $200 million bitcoin exchange for Semnur shares
-
Scilex enters crypto partnership with Biconomy for treasury management
-
Scilex agrees to exchange $200 million Semnur stock for bitcoin
-
SEC approves registration for Denali-Semnur business combination
-
Scilex Holding (SCLX) Announces Publication on GLOPERBA Dosing Adjustments in Peer-Review Journal
-
Scilex Holding (SCLX) Regains Nasdaq Compliance
-
Scilex Holding (SCLX) Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
-
Scilex Holding (SCLX) Announces Approval of NDS from Health Canada for ELYXYB®s Acute Treatment of Migraine With or Without Aura
-
D. Boral Capital Downgrades Scilex Holding Co. (SCLX) to Hold
-
Scilex Holding (SCLX) Announces 1-for-35 Reverse Stock Split
-
Scilex Holding (SCLX) Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to
-
D. Boral Capital Starts Scilex Holding Co. (SCLX) at Buy
-
Scilex Holding (SCLX) Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication
-
Scilex Holding (SCLX) Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
-
Scilex Holding (SCLX) Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
-
Scilex Holding (SCLX) Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication
-
Scilex Holding (SCLX) Amends its License Agreement with Romeg Therapeutics For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adult
-
Scilex Holding (SCLX) Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch
-
Scilex Holding (SCLX) Closes $17M Offering
-
Scilex Holding (SCLX) Announces $17 Million Registered Direct Offering
-
Scilex Holding (SCLX): Scilex Bio Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling
-
Scilex Holding (SCLX) announces binding term sheet to create commercial joint venture
-
Scilex Holding (SCLX) Announces Receipt of Notice from Nasdaq
-
Denali Capital Acquisition Corp. (DECA) Announces Extension of Deadline to Complete Business Combination
-
Scilex Holding (SCLX) Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA
-
H.C. Wainwright Reiterates Buy Rating on Scilex Holding Co. (SCLX)
-
Scilex Holding's (SCLX) Board Authorized Management to Explore Ways to Maximize the Value of Scilex Pharmaceuticals
-
Scilex Holding (SCLX) Provides Certain Preliminary Q3 Results
-
Scilex Holding (SCLX) Signs $50M Registered Convertible Financing
-
Scilex Holding (SCLX) Announces U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock
-
Scilex Holding (SCLX) Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million L

